The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes

OBJECTIVE Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion. However, GLP-1 also improves endothelial function in diabetes. RESEARCH DESIGN AND METHODS Sixteen type 2 diabetic patients and 12 control subjects received a meal, an oral glucose tolerance test (OGTT), and two hyperglycemic clamps, with or without GLP-1. The clamps were repeated in diabetic patients after 2 months of strict glycemic control. RESULTS During the meal, glycemia, nitrotyrosine, and plasma 8-iso prostaglandin F2α (8-iso-PGF2a) remained unchanged in the control subjects, whereas they increased in diabetic patients. Flow-mediated vasodilation (FMD) decreased in diabetes, whereas GLP-1 increased in both groups. During the OGTT, an increase in glycemia, nitrotyrosine, and 8-iso-PGF2a and a decrease in FMD were observed at 1 h in the control subjects and at 1 and 2 h in the diabetic patients. In the same way, GLP-1 increased in both groups at the same levels of the meal. During the clamps, in both the control subjects and the diabetic patients, a significant increase in nitrotyrosine and 8-iso-PGF2a and a decrease in FMD were observed, effects that were significantly reduced by GLP-1. After improved glycemic control, hyperglycemia during the clamps was less effective in producing oxidative stress and endothelial dysfunction and the GLP-1 administration was most effective in reducing these effects. CONCLUSIONS Our data suggest that during the meal GLP-1 can simultaneously exert an incretin effect on insulin secretion and a protective effect on endothelial function, reasonably controlling oxidative stress generation. The ability of GLP-1 in protecting endothelial function seems to depend on the level of glycemia, a phenomenon already described for insulin secretion.

[1]  R. D. de Boer,et al.  Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[2]  M. Nauck,et al.  Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? , 2010, Diabetes.

[3]  A. Peters Incretin-based therapies: review of current clinical trial data. , 2010, The American journal of medicine.

[4]  S. Mudaliar,et al.  Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. , 2010, The American journal of medicine.

[5]  P. Dandona,et al.  Insulin as an anti-inflammatory and antiatherogenic modulator. , 2009, Journal of the American College of Cardiology.

[6]  J. Holst,et al.  Four weeks of near‐normalization of blood glucose has no effect on postprandial GLP‐1 and GIP secretion, but augments pancreatic B‐cell responsiveness to a meal in patients with Type 2 diabetes , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[7]  Mark Ellrichmann,et al.  Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance , 2008, Diabetes.

[8]  J. McGill,et al.  The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. , 2005, Journal of the American College of Cardiology.

[9]  A. Ceriello Postprandial hyperglycemia and diabetes complications: is it time to treat? , 2005, Diabetes.

[10]  J. Holst,et al.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[11]  M. Quon,et al.  Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. , 2004, American journal of physiology. Heart and circulatory physiology.

[12]  E. Bonora,et al.  Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms , 2002, Circulation.

[13]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[14]  A. Ceriello,et al.  Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress , 2001, Diabetologia.

[15]  D. Drucker,et al.  Minireview: the glucagon-like peptides. , 2001, Endocrinology.

[16]  K. Kugiyama,et al.  Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. , 1999, Journal of the American College of Cardiology.

[17]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[18]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[19]  D. B. Zilversmit Atherogenesis: a postprandial phenomenon. , 1979, Circulation.

[20]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.